Magazine Article | October 14, 2009

Commercializing Biosimilars: Who Will Dominate The Market?

Source: Life Science Leader

By Cliff Mintz

The biopharmaceutical market, estimated to be about $40B annually, is one of the fastest-growing segments of the life sciences industry. It is growing four times as fast as the small-molecule market, and biopharmaceuticals are expected to represent 30% of all marketed drugs within the next five years. By 2010, as many as 13 blockbuster biopharmaceutical drugs with annual sales of $10B to $18B will lose patent protection. This, coupled with increasing downward pricing pressures for biopharmaceuticals and biologics, has created an enormous commercial opportunity for companies interested in developing biosimilars — also known as follow-on biologics (FOBs) — or lower-cost, generic versions of many blockbuster biopharmaceutical products.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: